Synopsys Shares Slide on Weak Guidance Despite Earnings Beat

BenzingaBenzinga
|||1 min read
Key Takeaway

Synopsys beat Q1 earnings but stock fell 3.44% on weak forward guidance, flat IP revenue, and China weakness concerns.

Synopsys Shares Slide on Weak Guidance Despite Earnings Beat

Synopsys Inc. shares declined 3.44% on Thursday following the semiconductor design software company's first-quarter earnings announcement, which exceeded profit expectations but fell short on forward guidance. The company reported adjusted earnings per share of $3.77 and revenue of $2.41 billion, surpassing analyst estimates. However, the positive earnings surprise was overshadowed by cautious second-quarter projections and concerning trends in key business segments.

The company's intellectual property revenue remained flat sequentially in the quarter, while second-quarter sales guidance came in below consensus expectations. These metrics prompted concern among investors about the sustainability of growth momentum, particularly as the company navigates macroeconomic headwinds. The guidance shortfall signals potential softness in near-term demand for Synopsys's core offerings.

Analyst Clarke Jeffries responded to the results by lowering the price target from $520 to $430 per share, citing underwhelming performance metrics and weakness in China revenue attributed to ongoing technology restrictions and geopolitical constraints. The analyst action reflects broader concerns about the company's exposure to international markets and the impact of trade limitations on its business outlook. The combination of tepid guidance and regional revenue challenges appears to have offset the company's ability to meet quarterly earnings targets.

Source: Benzinga

Back to newsPublished Feb 26

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO